# PDL-1 Targeting in Resectable Oesophageal Cancer

> **NCT03087864** · PHASE2 · COMPLETED · sponsor: **Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)** · enrollment: 40 (actual)

## Conditions studied

- Esophageal Cancer, Stage II
- Esophageal Cancer Stage III

## Interventions

- **DRUG:** Atezolizumab
- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel
- **RADIATION:** Radiotherapy 23 x 1.8 Gy

## Key facts

- **NCT ID:** NCT03087864
- **Lead sponsor:** Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-28
- **Primary completion:** 2019-07-01
- **Final completion:** 2019-07-01
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2020-05-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03087864

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03087864, "PDL-1 Targeting in Resectable Oesophageal Cancer". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT03087864. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*